Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S14 & S15 NDA 21-039/S13 & S14 10/2/02 10/11/01 10/3/02 Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S11 NDA 21-039/S10 8/2/02 8/6/02 8/5/02 Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S10, & 13 NDA 21-039/S9 & 12 2/5/02 4/17/02 Agenerase (amprenavir) Capsules and Solution, 50mg, 150mg Glaxo Wellcome NDA 21-007 NDA 21-039 4/15/99 7/24/02 5/25/99 7/24/02 Agenerase Indication: for the treatment of HIV-1 infection. | Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S6 NDA 21-039/S6 Agenerase (amprenavir) Capsules and Oral Solution, GlaxoSmithKline | AGENERASE (amprenavir) Capsules, GlaxoSmithKline, Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com